Precigen (NASDAQ:PGEN) Insider Donald Lehr Sells 29,131 Shares

Precigen, Inc. (NASDAQ:PGEN) insider Donald Lehr sold 29,131 shares of Precigen stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $127,011.16. Following the transaction, the insider directly owned 755,461 shares in the company, valued at $3,293,809.96. The trade was a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Trading Down 5.1%

PGEN traded down $0.22 during midday trading on Monday, hitting $4.12. 4,830,773 shares of the company were exchanged, compared to its average volume of 4,257,618. The firm has a market capitalization of $1.47 billion, a P/E ratio of -3.49 and a beta of 1.06. Precigen, Inc. has a 1-year low of $1.28 and a 1-year high of $5.47. The firm’s 50 day moving average price is $4.02 and its 200-day moving average price is $4.09. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. The firm had revenue of $23.25 million for the quarter, compared to the consensus estimate of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. As a group, equities analysts forecast that Precigen, Inc. will post 0.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PGEN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a research note on Sunday. Citizens Jmp boosted their price objective on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research note on Thursday, May 14th. Finally, HC Wainwright boosted their price objective on Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Precigen currently has an average rating of “Hold” and a consensus price target of $12.50.

Institutional Trading of Precigen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in Precigen during the 1st quarter worth approximately $27,000. NBC Securities Inc. bought a new stake in Precigen during the 4th quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd bought a new stake in Precigen during the 3rd quarter worth approximately $39,000. Royal Bank of Canada increased its holdings in Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in Precigen during the 3rd quarter worth approximately $41,000. 33.51% of the stock is owned by institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.